The KLHL25 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the KLHL25 gene in the human A-549 lung adenocarcinoma cell line. This product provides a heterogeneous pool of knockout cells, enabling robust loss-of-function analysis in a physiologically relevant epithelial context. By employing CRISPR/Cas9-mediated gene disruption, the model abolishes KLHL25 expression without introducing single-cell clonal selection, thereby preserving population-level diversity and reducing clonal artifacts. The polyclonal format is particularly suited for pooled functional screens, drug response profiling, and studies requiring a representative distribution of genetic variants within the knockout population.
The A-549 host cell line was originally derived from the lung adenocarcinoma of a 58-year-old Caucasian male and has been extensively characterized as a model of type II alveolar epithelial cells. These cells retain key features of alveolar epithelium, including surfactant production and tight junction formation, and they exhibit well-documented malignant properties such as anchorage-independent growth and tumorigenicity in xenograft models. As a mainstay in cancer research, A-549 cells are employed to investigate oncogenic signaling, metastasis mechanisms, and therapeutic responses in non-small cell lung carcinoma, making them a clinically relevant background for dissecting the molecular underpinnings of lung adenocarcinoma.
KLHL25 functions as a substrate-specific adaptor for the CUL3-RING E3 ubiquitin ligase complex (CRL3), which governs the ubiquitin-proteasome system. Within this complex, KLHL25 recruits target proteins such as the transcription factor ATF4 and the DDA1 protein, facilitating their ubiquitination by the catalytic core composed of CUL3 and RBX1 in conjunction with ubiquitin-conjugating enzymes. This process tags the substrates for proteasomal degradation, thereby regulating their abundance in response to cellular cues. KLHL25 activity is modulated by upstream stressors, including oxidative stress and endoplasmic reticulum stress, positioning it as a critical node in the integrated stress response. Consequently, disruption of KLHL25 leads to stabilization of ATF4 and DDA1, altering downstream transcriptional programs and protein homeostasis networks.
In the A-549 lung adenocarcinoma background, KLHL25 knockout offers a powerful tool to dissect the role of ubiquitin-mediated proteolysis in cancer cell biology. Given the frequent dysregulation of the ubiquitin-proteasome pathway in tumors, this model enables investigation of how loss of KLHL25 affects stress adaptation, protein quality control, and survival under therapeutic challenges. It is especially valuable for exploring the crosstalk between ER stress and oncogenic signaling, as well as for validating KLHL25 and its interaction partners, such as CUL3 and ATF4, as candidate drug targets. The model bridges basic mechanisms of protein degradation with translational research aimed at identifying vulnerabilities in lung adenocarcinoma cells.
This polyclonal knockout cell population is intended for a broad range of applications, including functional genomics studies to map CRL3 substrate networks, quantitative ubiquitination assays to monitor ATF4 and DDA1 stability, and cell-based screens to assess sensitivity to proteasome inhibitors or ER stress-inducing agents. Typical experimental readouts involve western blotting for target accumulation, RT-qPCR for stress-responsive transcripts, and viability assays under proteotoxic stress. Researchers can also employ this model in co-culture or three-dimensional culture systems to mimic tumor microenvironment interactions. For additional information about product specifications, validation data, or technical support, please contact Ascent Research.
